Biora Reports Positive Results on its Xeljanz Delivery Devices

Biora Therapeutics said that its ingestible medical devices for delivering a liquid formulation of tofacitinib, the active ingredient in Pfizer’s Xeljanz, showed promising results in a study.

No actual drugs were administered in the study, which was designed to assess whether the delivery devices were impacted if the patients had eaten food or were fasting. The results showed that all capsules were safely ingested and exited the body naturally in both groups, with no serious adverse events reported.

Xeljanz, a Janus Kinase Inhibitor, is FDA-approved for several indications, including for patients with moderate-to-severe active ulcerative colitis.

A separate study is now examining the drug delivery devices’ efficacy in active ulcerative colitis patients.